Cited by 967Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in CancerCancer-related Molecular Pathways

The DOI matches its Crossref record; 63 of the 70 references it cites were found in a registry or an index.

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α

Open access

Ravi, Rajani, Mookerjee, Bijoyesh, Bhujwalla, Zaver M., Sutter, Carrie Hayes, Artemov, Dmitri, Zeng, Qinwen, Dillehay, Larry E., Madan, Ashima, Semenza, Gregg L., Bedi, Atul·2000·Genes & Development

DOI 10.1101/gad.14.1.34

Open this paper in CoChat — free account Open PDF

Abstract

The switch to an angiogenic phenotype is a fundamental determinant of neoplastic growth and tumor progression. We demonstrate that homozygous deletion of the p53 tumor suppressor gene via homologous recombination in a human cancer cell line promotes the neovascularization and growth of tumor xenografts in nude mice. We find that p53 promotes Mdm2-mediated ubiquitination and proteasomal degradation of the HIF-1α subunit of hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that regulates cellular energy metabolism and angiogenesis in response to oxygen deprivation. Loss of p53 in tumor cells enhances HIF-1α levels and augments HIF-1-dependent transcriptional activation of the vascular endothelial growth factor (VEGF) gene in response to hypoxia. Forced expression of HIF-1α in p53-expressing tumor cells increases hypoxia-induced VEGF expression and augments neovascularization and growth of tumor xenografts. These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.14.1.34

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

THE UBIQUITIN SYSTEM
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Self-citation
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Self-citation
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“…ligase and is itself a target for Ub-mediated degradation via its interaction with Mdm2 (Momand et al. 1992; Barak et al. 1993; Wu et al. 1993; Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997), this raised the possibility that HIF-1a is recruited to Mdm2 via its interaction with p53.”
Background

Flagged first, then by citations

Show all 70 references

7 of the 70 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Kubbutat, 1997, Regulation of p53 stability by Mdm2., Nature, 387, 299, 10.1038/387299a0 · DOI · Paper page
Ravi, 1998, p53-mediated repression of nuclear factor κ-B RelA via the transcriptional integrator p 300., Cancer Res., 58, 4531
Zhong, 1999, Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases., Cancer Res., 59, 5830

Sorted by citations

Items 401–500 of 967

Improved diabetic wound healing through topical silencing of p53 is associated with augmented vasculogenic mediators
Nguyen, P. D., Tutela, J. P., Thanik, V. D., Knobel, D., Allen, R. J., Chang, C. C.-C., Levine, J. P., Warren, S. M., & Saadeh, P. B. (2010) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2010.00638.x · Cited by 63
Hypoxia-Inducible Factor in Thyroid Carcinoma
Burrows, N., Babur, M., Resch, J., Williams, K. J., & Brabant, G. E. (2011) · Journal of Thyroid Research · doi:10.4061/2011/762905 · Cited by 66
Structural, Functional, and Molecular MR Imaging of the Microvasculature
Neeman, M., & Dafni, H. (2003) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.5.040202.121606 · Cited by 62
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
Burkitt, K., Chun, S. Y., Dang, D. T., & Dang, L. H. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0944 · Cited by 61
Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression
Nahta, R., Al‐Mulla, F., Al-Temaimi, R. A., Amedei, A., Andrade-Vieira, R., Bay, S., Brown, D. G., Calaf, G. M., Castellino, R. C., Cohen-Solal, K., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv028 · Cited by 63
Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases
Liao, C., & Zhang, Q. H. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.04.003 · Cited by 64
Insulin-Like Growth Factor-II Regulates the Expression of Vascular Endothelial Growth Factor by the Human Keratinocyte Cell Line HaCaT
Kwon, Y., Kwon, K., Moon, H.-E., Park, J. A., Choi, K.-S., Kim, Y. S., Jang, H., Oh, C., Lee, Y. M., Kwon, Y., et al. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22735.x · Cited by 60
Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1α mediated by the PTEN/PI3K/Akt pathway
Park, J.-H., Lee, J.-Y., Shin, D.-H., Jang, K.-S., Kim, H.-J., & Kong, G. (2011) · Oncogene · doi:10.1038/onc.2011.174 · Cited by 60
Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs
Zhang, Y., Li, J., Lai, X., Jiao, X., Xiong, J., & Xiong, L. (2019) · Cells · doi:10.3390/cells8020146 · Cited by 63
Properties of Switch-like Bioregulatory Networks Studied by Simulation of the Hypoxia Response Control System
Kohn, K. W., Riss, J., Aprelikova, O. N., Weinstein, J. N., Pommier, Y. G., & Barrett, J. C. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-12-0897 · Cited by 61
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma
Borsi, E., Terragna, C., Brioli, A., Tacchetti, P., Martello, M., & Cavo, M. (2014) · Translational research · doi:10.1016/j.trsl.2014.12.001 · Cited by 61
Expression of the RNA Helicase DDX3 and the Hypoxia Response in Breast Cancer
Bol, G. M., Raman, V., van der Groep, P., Vermeulen, J. F., Patel, A. H., van der Wall, E., & van Diest, P. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063548 · Cited by 59
Constitutive upregulation of hypoxia-inducible factor-1α mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure
Koshikawa, N., Iyozumi, A., Gassmann, M., & Takenaga, K. (2003) · Oncogene · doi:10.1038/sj.onc.1206765 · Cited by 59
Angiogenesis in ovarian cancer
Brown, M. R., Blanchette, J. O., & Kohn, E. C. (2000) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1053/beog.2000.0134 · Cited by 59
Hyperoxic Ventilated Premature Baboons Have Increased p53, Oxidant DNA Damage and Decreased VEGF Expression
Maniscalco, W. M., Watkins, R. H., Roper, J. M., Staversky, R. J., & O’Reilly, M. A. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000176923.79584.f7 · Cited by 59
Mechanisms of Disease: angiogenesis in urologic malignancies
Charlesworth, P. J. S., & Harris, A. L. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0434 · Cited by 59
The vascular endothelial growth factor family and its receptors
Parikh, A. A., & Ellis, L. M. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.06.004 · Cited by 60
Impact of Oncogenes and Tumor Suppressor Genes on Deregulation of Hemostasis and Angiogenesis in Cancer
Rak, J. W., & Klement, G. (2000) · Cancer and Metastasis Reviews · doi:10.1023/a:1026516920119 · Cited by 59
HIF-1α and p53: the ODD couple?
Fels, D. R., & Koumenis, C. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.06.009 · Cited by 63
Suppression of the Hypoxia-Inducible Factor-1 Response in Cervical Carcinoma Xenografts by Proteasome Inhibitors
Birle, D. C., & Hedley, D. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2722 · Cited by 58
Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1α pre-mRNA in mice and in vitro
Lee, Y.-M., Lim, J.-H., Yoon, H., Chun, Y., & Park, J. (2010) · Hepatology · doi:10.1002/hep.24010 · Cited by 58
The oncogenic potential of NANOG: An important cancer induction mediator
Najafzadeh, B., Asadzadeh, Z., azad, R. M., Mokhtarzadeh, A., Baghbanzadeh, A., Alemohammad, H., Shadbad, M. A., Vasefifar, P., Najafi, S., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30063 · Cited by 58
Novel Function of Orphan Nuclear Receptor Nur77 in Stabilizing Hypoxia-inducible Factor-1α
Yoo, Y., Yeo, M. G., Kim, D. K., Park, H., & Lee, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408554200 · Cited by 58
Selective Inactivation of p53 Facilitates Mouse Epithelial Tumor Progression without Chromosomal Instability
Lu, X., Magrane, G., Yin, C., Louis, D. N., Gray, J. W., & Dyke, T. V. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.6017-6030.2001 · Cited by 55
Hypoxia Inducible Factor-1alpha and Vascular Endothelial Growth Factor in Biopsies of Small Cell Lung Carcinoma
Ioannou, M., Papamichali, R., Kouvaras, E., Mylonis, I., Vageli, D., Kerenidou, T., Barbanis, S., Daponte, A., Simos, G., Gourgoulianis, K., et al. (2009) · Lung · doi:10.1007/s00408-009-9169-z · Cited by 57
Targeting HIF-1α by Natural and Synthetic Compounds: A Promising Approach for Anti-Cancer Therapeutics Development
Ghosh, R., Samanta, P., Sarkar, R., Biswas, S., Saha, P., Hajra, S., & Bhowmik, A. (2022) · Molecules · doi:10.3390/molecules27165192 · Cited by 65
Recurrent pregnancy failure is associated with a polymorphism in the p53 tumour suppressor gene
Pietrowski, D., Bettendorf, H., Riener, E., Keck, C., Hefler, L., Huber, J. C., & Tempfer, C. M. (2004) · Human Reproduction · doi:10.1093/humrep/deh696 · Cited by 57
Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer
Isobe, T., Aoyagi, K., KOUFUJI, K., Shirouzu, K., Kawahara, A., Taira, T., & Kage, M. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0378-8 · Cited by 58
The p53 status in rheumatoid arthritis with focus on fibroblast-like synoviocytes
Taghadosi, M., Adib, M., Jamshidi, A., Mahmoudi, M., & Farhadi, E. (2021) · Immunologic Research · doi:10.1007/s12026-021-09202-7 · Cited by 58
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin
Donahue, R. N., McLaughlin, P. J., & Zagon, I. S. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011096 · Cited by 56
Hypoxia-inducible factor-1 alpha regulates prion protein expression to protect against neuron cell damage
Jeong, J., Seo, J., Moon, M., Lee, Y.-J., Seol, J., & Park, S. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.037 · Cited by 56
Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer
Liu, G., Claret, F. X., Zhou, F., & Pan, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00135 · Cited by 57
The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.
Liu, F., You, X., Wang, Y., Liu, Q., Liu, Y.-X., Zhang, S.-Q., Chen, L.-Y., Zhang, X.-D., & Ye, L. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu021 · Cited by 55
Visualizing vascular permeability and lymphatic drainage using labeled serum albumin
Vandoorne, K., Addadi, Y., & Neeman, M. (2010) · Angiogenesis · doi:10.1007/s10456-010-9170-4 · Cited by 54
Diminished Carcinogen Detoxification Is a Novel Mechanism for Hypoxia-inducible Factor 1-mediated Genetic Instability
Schults, M. A., Timmermans, L., Godschalk, R., Theys, J., Wouters, B. G., van Schooten, F., & Chiu, R. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.076323 · Cited by 56
Molecular interactions of ‘high risk’ human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression
Chakrabarti, O., & Krishna, S. (2003) · Journal of Biosciences · doi:10.1007/bf02970152 · Cited by 55
Upregulation of Hypoxia-Inducible Factor-1α mRNA and its Clinical Significance in Non-small Cell Lung Cancer
Yohena, T., Yoshino, I., Takenaka, T., 亀山, 敏., Ohba, T., Kuniyoshi, Y., & Maehara, Y. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819852d5 · Cited by 54
BP-1T, an antiangiogenic benzophenone-thiazole pharmacophore, counteracts HIF-1 signalling through p53/MDM2-mediated HIF-1α proteasomal degradation
Thirusangu, P., Vigneshwaran, V., Prashanth, T., Avin, B. R. V., Malojirao, V. H., Rakesh, H., Khanum, S. A., Mahmood, R., & Prabhakar, B. T. (2016) · Angiogenesis · doi:10.1007/s10456-016-9528-3 · Cited by 53
The HIF-1α as a Potent Inducer of the Hallmarks in Gastric Cancer
Metin, C. U., & Özcan, G. (2022) · Cancers · doi:10.3390/cancers14112711 · Cited by 56
The Role of Reprogrammed Glucose Metabolism in Cancer
Ediriweera, M. K., & Jayasena, S. (2023) · Metabolites · doi:10.3390/metabo13030345 · Cited by 55
Unraveling the role of HIF-1α in sepsis: from pathophysiology to potential therapeutics—a narrative review
Ruan, H., Zhang, Q., Zhang, Y., Li, S., & Ran, X. (2024) · Critical Care · doi:10.1186/s13054-024-04885-4 · Cited by 60
Vascular Endothelial Growth Factor Pharmacogenetics: a New Perspective for Anti-Angiogenic Therapy
Pasqualetti, G., Danesi, R., Tacca, M. D., & Bocci, G. (2006) · Pharmacogenomics · doi:10.2217/14622416.8.1.49 · Cited by 54
Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer
Nalwoga, H., Ahmed, L., Arnes, J. B., Wabinga, H., & Akslen, L. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146823 · Cited by 55
MutatedTP53is a marker of increasedVEGFexpression: analysis of 7,525 pan-cancer tissues
Li, A. M., Boichard, A., & Kurzrock, R. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1665956 · Cited by 53
Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia
Kamat, C. D., Green, D. E., Warnke, L. A., Thorpe, J. E., Ceriello, A., & Ihnat, M. A. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.08.017 · Cited by 53
Specific Inhibition of Hypoxia-inducible Factor (HIF)-1.ALPHA. Activation and of Vascular Endothelial Growth Factor (VEGF) Production by Flavonoids
Hasebe, Y., Egawa, K., Yamazaki, Y., Kunimoto, S., Hirai, Y., Ida, Y., & Nose, K. (2003) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.26.1379 · Cited by 52
Vascular proliferation is increased in basal-like breast cancer
Nalwoga, H., Arnes, J. B., Stefansson, I. M., Wabinga, H., Foulkes, W. D., & Akslen, L. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1740-7 · Cited by 52
p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth
Hayashi, Y., Tsujii, M., Kodama, T., Akasaka, T., Kondo, J., Hikita, H., Inoue, T., Tsujii, Y., Maekawa, A., Yoshii, S., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw085 · Cited by 51
A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma
Oh, E., Hong, J., Kwon, O., & Yun, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-19300-6 · Cited by 51
Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes
Hayashi, Y., Zhang, Y., Yokota, A., Yan, X., Liu, J., Choi, K., Li, B., Sashida, G., Peng, Y., Xu, Z., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1203 · Cited by 54
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer
Goffin, J., Straume, O., Chappuis, P. O., Brunet, J., Bégin, L. R., Hamel, N., Wong, N., Akslen, L., & Foulkes, W. D. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601195 · Cited by 52
Inhibitor of DNA Binding 1 Activates Vascular Endothelial Growth Factor through Enhancing the Stability and Activity of Hypoxia-Inducible Factor-1α
Kim, H., Chung, H., Yoo, Y., Kim, I. H., Lee, J., Lee, M., & Kong, G. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0218 · Cited by 51
Gamma rays induce a p53-independent mitochondrial biogenesis that is counter-regulated by HIF1α
Bartoletti‐Stella, A., Mariani, E., Kurelac, I., Maresca, A., Caratozzolo, M. F., Iommarini, L., Carelli, V., Eusebi, L. H., Guido, A., Cenacchi, G., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.187 · Cited by 52
Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy
Guo, J., Mihic, A., Wu, J., Zhang, Y., Singh, K., Dhingra, S., Weisel, R. D., & Li, R. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv294 · Cited by 51
Association of increased ligand cyclophilin A and receptor CD147 with hypoxia, angiogenesis, metastasis and prognosis of tongue squamous cell carcinoma
Huang, C., Sun, Z., Sun, Y., Chen, X., Zhu, X., Fan, C., Liu, B., Zhao, Y., & Zhang, W. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.04130.x · Cited by 51
An Overview of Cyclophilins in Human Cancers
Lee, J., & Kim, S. S. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800501 · Cited by 54
Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats
Beck, J., Henschel, C., Chou, J., Lin, A., & del Balzo, U. (2017) · International Journal of Toxicology · doi:10.1177/1091581817737232 · Cited by 51
Current Paradigms in Cellular Oxygen Sensing
Schumacker, P. T. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8997-0_5 · Cited by 51
Increased expression of hypoxia-inducible factor 1α in type I and type II endometrial carcinomas
Pansare, V. M., Munkarah, A. R., Schimp, V. L., Arabi, H., Saed, G. M., Morris, R. T., & Ali‐Fehmi, R. (2006) · Modern Pathology · doi:10.1038/modpathol.3800718 · Cited by 51
Chemoprevention Strategies with Cyclooxygenase-2 Inhibitors for Lung Cancer
Mao, J. T., Cui, X., Reckamp, K. L., Liu, M., Krysan, K., Dalwadi, H. N., Sharma, S. P., Hazra, S., Strieter, R. M., Gardner, B. K., et al. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.n.019 · Cited by 51
Molecular Pathways for Cancer Angioprevention
Albini, A., Noonan, D. M., & Ferrari, N. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0069 · Cited by 51
Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 -deficient mouse embryonic fibroblasts
Wirthner, R., Wrann, S., Balamurugan, K., Wenger, R. H., & Stiehl, D. P. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn231 · Cited by 51
Small molecules targeting HIF-1α pathway for cancer therapy in recent years.
Tang, W., & Zhao, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115235 · Cited by 50
Tumor Hypoxia Imaging
Serganova, I., Humm, J., Ling, C., & Blasberg, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0517 · Cited by 50
Hypoxia inducible factor‐1 alpha plays a pivotal role in hepatic metastasis of pancreatic cancer: an immunohistochemical study
Matsuo, Y., Ding, Q., Desaki, R., Maemura, K., Mataki, Y., Shinchi, H., Natsugoe, S., & Takao, S. (2014) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.6 · Cited by 50
Neural crest delamination and migration: Looking forward to the next 150 years
Gouignard, N., Andrieu, C., & Théveneau, E. (2018) · genesis · doi:10.1002/dvg.23107 · Cited by 51
Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas
Birlik, B., Canda, Ş., & Özer, E. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00763.x · Cited by 50
Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy
Bussink, J., Kaanders, J. H. A. M., & van der Kogel, A. J. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.10.022 · Cited by 50
Association of p53 polymorphism with ICSI/IVF failure and recurrent pregnancy loss
Firouzabadi, R. D., Ghasemi, N., ROZBAHANI, M. A., & Tabibnejad, N. (2009) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2009.00972.x · Cited by 49
Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1α
Lee, Y.-M., Lim, J.-H., Chun, Y., Moon, H.-E., Lee, M. K., Huang, E. L., & Park, J. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp196 · Cited by 49
Novel Thioredoxin Inhibitors Paradoxically Increase Hypoxia-Inducible Factor-α Expression but Decrease Functional Transcriptional Activity, DNA Binding, and Degradation
Jones, D. T., Pugh, C. W., Wigfield, S., Stevens, M. F. G., & Harris, A. L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2380 · Cited by 48
Tumour hypoxia in driving genomic instability and tumour evolution
Suvac, A., Ashton, J., & Bristow, R. G. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00781-9 · Cited by 60
Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment
Wierzbicki, P., Kłącz, J., Kotulak‐Chrząszcz, A., Wrońska, A., Stanisławowski, M., Rybarczyk, A., Ludziejewska, A., Kmieć, Z., & Matuszewski, M. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4830 · Cited by 49
Basic Biology of Hypoxic Responses Mediated by the Transcription Factor HIFs and Its Implication for Medicine
Hirota, K. (2020) · Biomedicines · doi:10.3390/biomedicines8020032 · Cited by 52
Dendritic cell vaccine therapy for colorectal cancer
McCormick, A. L., Girgis, L. H., Brazeale, H. S., Anderson, T. S., Wood, L. M., & Lowe, D. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105374 · Cited by 48
Hypoxic induction of hypoxia-inducible factor-1α and oxygen-regulated gene expression in mitochondrial DNA-depleted HeLa cells
Enomoto, N., Koshikawa, N., Gassmann, M., Hayashi, J., & Takenaga, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02186-1 · Cited by 49
Involvement of RB gene family in tumor angiogenesis
Gabellini, C., Del Bufalo, D., & Zupi, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209631 · Cited by 47
Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxia
Goto, K., Asai, T., Hara, S., Namatame, I., Tomoda, H., Ikemoto, M., & Oku, N. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.07.034 · Cited by 47
Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin
Folkman, J. (2006) · Science s STKE · doi:10.1126/stke.3542006pe35 · Cited by 47
Involvement of stromal p53 in tumor-stroma interactions
Bar, J., Moskovits, N. B.-C., & Oren, M. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.11.006 · Cited by 49
Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells
Tomita, M., Semenza, G. L., Michiels, C., Matsuda, T., Uchihara, J., Okudaira, T., Tanaka, Y., Taira, N., Ohshiro, K., & Mori, N. (2007) · Biochemical Journal · doi:10.1042/bj20070286 · Cited by 47
Self-citation
Retracted
Regulation of Angiogenic Factors by HDM2 in Renal Cell Carcinoma
Carroll, V. A., & Ashcroft, M. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-06-4738 · Cited by 47
Macrophage Motility in Wound Healing Is Regulated by HIF-1α via S1P Signaling
Hutami, I. R., Izawa, T., Khurel‐Ochir, T., Sakamaki, T., Iwasa, A., & Tanaka, E. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168992 · Cited by 49
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice
Donahue, R. N., McLaughlin, P. J., & Zagon, I. S. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.04.009 · Cited by 45
TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma
Caratozzolo, M. F., Valletti, A., Gigante, M., Aiello, I., Mastropasqua, F., Marzano, F., Ditonno, P., Carrieri, G., Simonnet, H., D’Erchia, A. M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2081 · Cited by 45
Annexin A1 is involved in resistance to 5-FU in colon cancer cells
Onozawa, H., Saito, M., Saito, K., Kanke, Y., Watanabe, Y., Hayase, S., Sakamoto, W., Ishigame, T., Momma, T., Ohki, S., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.5234 · Cited by 45
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study
Secord, A. A., Darcy, K. M., Hutson, A. D., Lee, P. S., Havrilesky, L. J., Grace, L. A., & Berchuck, A. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.03.021 · Cited by 45
The labdane diterpene sclareol (labd-14-ene-8, 13-diol) induces apoptosis in human tumor cell lines and suppression of tumor growth in vivo via a p53-independent mechanism of action
Mahaira, L. G., Tsimplouli, C., Sakellaridis, N., Alevizopoulos, K., Demetzos, C., Han, Z., Pantazis, P., & DIMAS, K. S. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.065 · Cited by 46
The intricate interplay between HIFs, ROS, and the ubiquitin system in the tumor hypoxic microenvironment
Wang, Y., Liu, X., Huang, W., Liang, J., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108303 · Cited by 44
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015)
Ban, H. S., Uto, Y., Won, M., & Nakamura, H. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1146252 · Cited by 45
Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6
Merkel, C. A., Soares, R. B. D. S., de Carvalho, A. C. V., Zanatta, D. B., Bajgelman, M. C., Fratini, P., Costanzi-Strauss, E., & Strauss, B. E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-316 · Cited by 43
Hypoxia inhibits mesenchymal stem cell proliferation through HIF1α-dependent regulation of P27
Kumar, S., & Vaidya, M. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2674-5 · Cited by 43
Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer
Gomez-Roman, N., Sahasrabudhe, N. M., McGregor, F., Chalmers, A. J., Cassidy, J., & Plumb, J. A. (2016) · Oncotarget · doi:10.18632/oncotarget.7998 · Cited by 43
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53
Makii, C., Oda, K., Ikeda, Y., Sone, K., Hasegawa, K., Uehara, Y., Nishijima, A., Asada, K., Koso, T., Fukuda, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12175 · Cited by 44
P53 tumor suppressor factor, plasminogen activator inhibitor, and vascular endothelial growth factor gene polymorphisms and recurrent implantation failure
Goodman, C., Jeyendran, R., & Coulam, C. B. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.07.022 · Cited by 43
Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer
Perrone, G., Vincenzi, B., Santini, D., Verzì, A., Tonini, G., Vetrani, A., & Rabitti, C. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.11.032 · Cited by 43
Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery
Talekar, M., Boreddy, S. R., Singh, A., & Amiji, M. M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.912270 · Cited by 42
Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010)
Ban, H. S., Uto, Y., & Nakamura, H. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.547477 · Cited by 42
E2F1 suppresses cardiac neovascularization by down-regulating VEGF and PlGF expression
Wu, M., Zhou, J., Cheng, M., Boriboun, C., Biyashev, D., Wang, H., Mackie, A. R., Thorne, T. E., Chou, J. C., Wu, Y., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu222 · Cited by 41
Roles of hypoxia, stem cells and epithelial–mesenchymal transition in the spread and treatment resistance of head and neck cancer
Gammon, L., & Mackenzie, I. C. (2015) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12327 · Cited by 44

Authors: Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A.
Affiliations: Johns Hopkins University (US)
ORCID: Bhujwalla, Zaver M.
Artemov, Dmitri
Semenza, Gregg L.
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2000-01-01
Volume: 14
Issue: 1
Pages: 34-44
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.14.1.34
OpenAlex: W4294718043
Semantic Scholar: 5c0770cda1be256df47794076979768b0350af33
Cited by: 967
References: 70
Citations by year: 2026: 19 · 2025: 23 · 2024: 35 · 2023: 28 · 2022: 35 · 2021: 35 · 2020: 33 · 2019: 25 · 2018: 30 · 2017: 25 · 2016: 35 · 2015: 41 · 2014: 36 · 2013: 34 · 2012: 32
Type: posted content
Language: en
Open access: bronze
doi.org
Locations: Genes & Development (publishedVersion)
Funders: U.S. Department of Defense
American Cancer Society
National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords: tumor angiogenesis, p53, hypoxia-inducible factor-1α, MDM2, ubiquitination, proteasomal degradation, vascular endothelial growth factor, hypoxia, neovascularization, tumor xenografts, angiogenic switch, tumor suppressor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks